Compare Lumen Technologies Inc (LUMN) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lumen Technologies Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Lumen Technologies Inc trades at $5.29 (market cap $5.73B), while Vertex Pharmaceuticals Incorporated trades at $509.5 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 22.3× Lumen Technologies Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Lumen Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lumen Technologies Inc for 40 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| LUMN | VRTX | |
|---|---|---|
Market Cap | $5.73B | $127.55B |
Volume | 17,079,799 | 1,487,944 |
Sector | Media | Health |
52-Week High | $11.83 | $557.96 |
52-Week Low | $5.53 | $407.37 |
Typical Hold Time | 40 Days | 120 Days |
Enterprise Value | $17.35B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lumen Technologies (LUMN) trades at $5.28, down 10.66% in the last session, reflecting ongoing investor concerns. The stock shows bearish technical signals with mixed earnings performance - beating estimates in Q4 2025 and Q2 2026 but missing in Q1 2026. Despite revenue declining from $17.5B in 2022 to $12.4B in 2025, the company maintains strong operating cash flow of $4.7B and is strategically pivoting toward AI networking services.
LUMN presents a high-risk turnaround opportunity with significant debt burden ($17.5B long-term) and negative profitability metrics. The AI-focused strategy shows promise but faces execution risk against steep legacy revenue declines. Analyst consensus remains cautious with 61% hold ratings, suggesting investors await concrete evidence of sustainable growth before committing.
Vertex Pharmaceuticals (VRTX) trades at $510.08, up 0.88% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong 2025 results with $12B revenue and $4B net income, though recent quarterly earnings show inconsistent performance against expectations. Positive Phase 2b data for inaxaplin in kidney disease highlights pipeline progress beyond cystic fibrosis dominance.
Wall Street maintains strong bullish sentiment with 84% buy ratings and $573.50 consensus target, but risks include competitive pressures and reliance on CF franchise. The stock's premium valuation (P/E 29.31) requires continued execution on pipeline expansion to justify upside potential amid technical resistance near $515.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lumen Technologies Inc
With 450,000 route miles of fiber, including over 35,000 route miles of subsea fiber connecting Europe, Asia, and Latin America, Lumen Technologies is one of the United States' largest telecommunications carriers serving global enterprises. Its merger with Level 3 further shifted the company's operations toward businesses (over 70% of revenue) and away from its legacy consumer business. Lumen offers businesses a full menu of communications services, providing colocation and data center services, data transportation, and end-user phone and internet service. On the consumer side, Lumen provides broadband and phone service across 37 states, where it has 4.5 million broadband customers.
Read more on LUMN →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
